Erratum: Protein kinase C: A putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro (Endocrinology (2012) 153 (2088-2098) DOI: 10.1210/en.2011-1988);Protein kinase C: A putative new target for the control of human medullary thyroid carcinoma cell proliferation in Vitro

Endocrinology

Volumn 153, Issue 5, 2012, Pages 2088-2098

  Molè, Daniela ^a   Gentilin, Erica ^a,c   Gagliano, Teresa ^a   Tagliati, Federico ^a   Bondanelli, Marta ^a   Pelizzo, Maria Rosa ^d   Rossi, Martina ^a   Filieri, Carlo ^a   Pansini, Giancarlo ^b   Degli Uberti, Ettore C ^a,c   Zatelli, Maria Chiara ^a,c  

^a Geriatrics and Internal Medicine   (Italy)

^b and Radiological Sciences   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CASPASE; ENZASTAURIN; GLYCOGEN SYNTHASE KINASE; ISOENZYME; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; SOMATOMEDIN C;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LOCALIZATION; FEMALE; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID MEDULLARY CARCINOMA;

EID: 84860332805     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-2135     Document Type: Erratum

References (47)

1. Hug H, Sarre TF 1993 Protein kinase C isoenzymes: divergence in signal transduction? Biochem J 291:329-343 (Pubitemid 23127010)
2. Musashi M, Ota S, Shiroshita N 2000 The role of protein kinase C isoforms in cell proliferation and apoptosis. Int J Hematol 72:12-19
3. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC 2001 Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98:428-435
4. Mendez CF, Leibiger IB, Leibiger B, Høy M, Gromada J, Berggren PO, Bertorello AM 2003 Rapid association of protein kinase C-epsilon with insulin granules is essential for insulin exocytosis. J Biol Chem 278:44753-44757 (Pubitemid 37377233)
5. Vasavada RC, Wang L, Fujinaka Y, Takane KK, Rosa TC, Mellado-Gil JM, Friedman PA, Garcia-Ocaña A 2007 Protein kinase C-ζ activation markedly enhances β-cell proliferation: an essential role in growth factor mediated β-cell mitogenesis. Diabetes 56:2732-2743 (Pubitemid 350044916)
6. Koivunen J, Aaltonen V, Peltonen J 2006 Protein kinase C (PKC) family in cancer progression. Cancer Lett 235:1-10
7. Wetsel WC, Khan WA, Merchenthaler I, Rivera H, Halpern AE, Phung HM, Negro-Vilar A, Hannun YA 1992 Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol 117:121-133
8. Molè D, Gagliano T, Gentilin E, Tagliati F, Pasquali C, Ambrosio MR, Pansini G, Degli Uberti EC, Zatelli MC 2011 Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in hu- man pancreatic endocrine tumors. Endocr Relat Cancer 18:439-450
9. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A 2007 RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92: 4725-4729 (Pubitemid 350223450)
10. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K 2010 The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39:775-783
11. Pacini F, Castagna MG, Cipri C, Schlumberger M 2010 Medullary thyroid carcinoma. Clin Oncol 22:475-485
12. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801
13. Cakir M, Grossman AB 2009 Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 90: 323-348
14. Capurso G, Fazio N, Festa S, Panzuto F, De Braud F, Delle Fave G 2009 Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. Crit Rev Oncol Hematol 72:110-124
15. Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, Radice MT, Pierotti MA 1996 The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase C7. Mol Cell Biol 16:2151-2163 (Pubitemid 26123736)
16. Sobin LH, Gospodarowicz MK, Wittekind C 2009 TNM classification of malignant tumours. Oxford: Wiley-Blackwell, 58-62
17. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, Vignali C, Bondanelli M, degli Uberti EC 2005 Cyclooxigenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a P-gp mediated mechanism. J Clin Endocrinol Metab 90:5754-5760 (Pubitemid 41415487)
18. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, degli Uberti EC 2002 Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 297:828-834
19. Leong SS, Horoszewicz JS, Shimaoka K 1981 A new cell line for study of human medullary carcinoma. In: Andreoli MT, ed. Advances in thyroid neoplasia. Rome: Field Educational; 95-108
20. Cooley LD, Elder FF, Knuth A, Gagel RF 1995 Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. Cancer Genet Cytogenet 80:138-149
21. Frendo JL, Pichaud F, Mourroux RD, Bouizar Z, Segond N, Moukhtar MS, Jullienne A 1994 An isoform of the human calcitonin receptor is expressed in TT cells and in medullary carcinoma of the thyroid. FEBS Lett 342:214-216 (Pubitemid 24115199)
22. Zabel M, Seidel J, Kaczmarek A, Surdyk-Zasada J, Grzeszkowiak J, Górny A 1994 Hybridocytochemical and immuno-ultrastructural study of calcitonin gene expression in cultured medullary carcinomas cells. Histochemistry 102:323-327
23. Tagliati F, Zatelli MC, Bottoni A, Piccin D, Luchin A, Culler MD, Degli Uberti EC 2006 Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a[1] medullary thyroid carcinoma cell line in vitro. Endocrinology 147:3530-3538 (Pubitemid 43901144)
24. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D 2005 The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462-7469 (Pubitemid 41161281)
25. Spalding AC, Watson R, Davis ME, Kim AC, Lawrence TS, Ben-Josef E 2007 Inhibition of protein kinase Cβ by enzastaurin enhances radiation cytotoxicity in pancreatic cancer. Clin Cancer Res 13:6827-6833 (Pubitemid 350206821)
26. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB 2002 Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by ly-sophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22:2099-2110 (Pubitemid 34224618)
27. Goode N, Hughes K, Woodgett JR, Parker PJ 1992 Differential regulation of glycogen synthase kinase-3β by protein kinase C isotypes. J Biol Chem 267:16878-16882
28. Goekjian PG, Jirousek MR 2001 Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10:2117-2140 (Pubitemid 34000377)
29. Knauf JA, Ward LS, Nikiforov YE, Nikiforova M, Puxeddu E, Medvedovic M, Liron T, Mochly-Rosen D, Fagin JA 2002 Isozyme-specific abnormalities of PKC in thyroid cancer: evidence for post-transcriptional changes in PKC epsilon. J Clin Endocrinol Metab 87:2150-2159 (Pubitemid 34521502)
30. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatji-harissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM 2007 Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobu-linemia. Blood 109:4964-4972 (Pubitemid 46827795)
31. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS 2006 Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase Cβ inhibitor, in patients with advanced cancer. J Clin Oncol 24:4092-4099 (Pubitemid 46622284)
32. Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO 2000 Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 279:L429-L438
33. Chiarini A, Whitfield JF, Armato U, Dal Pra I 2002 Protein Kinase C-βII is an apoptotic lamin kinase in polyomavirus-transformed, etoposide-treated pyF111 rat fibroblasts. J Biol Chem 277:18827-18839 (Pubitemid 34952442)
34. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M 2001 Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 7:634-640 (Pubitemid 32707989)
35. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM 2001 Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts. Cancer Chemother Pharmacol 48:473-480 (Pubitemid 33139869)
36. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM 2002 Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 20:241-251 (Pubitemid 34823752)
37. Care AD, Abbas SK, Pell J, Seitz PK, Cooper CW 1998 Stimulatory effect of insulin on calcitonin secretion. Horm Metab Res 30:200-205 (Pubitemid 28201087)
38. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ 2010 Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J Clin Endocrinol Metab 95:E26-E31
39. Wong CK, Lai T, Holly JM, Wheeler MH, Stewart CE, Farndon JR 2006 Insulin-like growth factors (IGF) I and II utilize different calcium signaling pathways in a primary human parathyroid cell culture model. World J Surg 30:333-345 (Pubitemid 43261357)
40. Freichel M, Zink-Lorenz A, Holloschi A, Hafner M, Flockerzi V, Raue F 1996 Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion. Endocrinology 137:3842-3848 (Pubitemid 26284655)
41. Giovannetti E, Honeywell R, Hanauske AR, Tekle C, Kuenen B, Sigmond J, Giaccone G, Peters GJ 2010 Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets 11:12-28
42. Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST 2006 Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 5:1783-1789 (Pubitemid 44323246)
43. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sab-harwal SS, Krett NL, Rosen ST 2006 The selective protein kinase Cβ inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126: 1641-1647
44. Cerrato A, De Falco V, Santoro M 2009 Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 43:143-155
45. Scheid MP, Marignani PA, Woodgett JR 2002 Multiple phospho-inositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 22:6247-6260 (Pubitemid 34857843)
46. Newton AC 2001 Protein kinase c: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 101:2353-2364 (Pubitemid 35373023)
47. Kawakami T, Kawakami Y, Kitaura J 2002 Protein kinase Cβ (PKCβ): normal functions and diseases. J Biochem 132:677-682 (Pubitemid 35408488)